BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Dall'Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V, Treglia G, Racca M, Annunziata S. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor? Cancers (Basel) 2022;14:4039. [PMID: 36011032 DOI: 10.3390/cancers14164039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R, Vento A, Pacella S, Camedda R, Caracciolo M, De Feo MS, Mammucci P, Frantellizzi V, Ortolan N, Fiasconaro E, Urso L, Evangelista L, Laudicella R, Santo G. PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. Life 2023;13:611. [DOI: 10.3390/life13030611] [Reference Citation Analysis]
2 Rizzo A, Racca M, Dall'Armellina S, Delgado Bolton RC, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G. Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review. Diagnostics (Basel) 2023;13. [PMID: 36766670 DOI: 10.3390/diagnostics13030564] [Reference Citation Analysis]
3 Rizzo A, Racca M, Dall'Armellina S, Rescigno P, Banna GL, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers (Basel) 2023;15. [PMID: 36672305 DOI: 10.3390/cancers15020355] [Reference Citation Analysis]
4 Rizzo A, Racca M, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G. Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis. Pharmaceuticals 2022;15:1368. [DOI: 10.3390/ph15111368] [Reference Citation Analysis]